Technical Analysis for IDRA - Idera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 2.72 -9.33% -0.28
IDRA closed down 9.33 percent on Friday, March 22, 2019, on 1.63 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical IDRA trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 Fell Below 50 DMA Bearish 0.00%
Mar 22 BB Squeeze Ended Range Expansion 0.00%
Mar 21 Bollinger Band Squeeze Range Contraction -9.33%
Mar 21 BB Squeeze + Upper Band Touch Range Contraction -9.33%
Mar 21 Inside Day Range Contraction -9.33%
Mar 21 Upper Bollinger Band Touch Strength -9.33%
Mar 20 Pocket Pivot Bullish Swing Setup -13.65%
Mar 20 Bollinger Band Squeeze Range Contraction -13.65%
Mar 20 Upper Bollinger Band Walk Strength -13.65%

Older signals for IDRA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. It is developing drug candidates designed to modulate immune responses mediated through Toll-like Receptors (TLRs); and evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. The company focuses on developing products for the treatment of autoimmune and inflammatory diseases. Its autoimmune and inflammatory disease programs include IMO-3100, an antagonist of TLR7 and TLR9, which has completed Phase II clinical trials for the treatment of psoriasis; and IMO-8400, an antagonist of TLR7, TLR8, and TLR9 that is in Phase I clinical trials for the treatment of psoriasis/lupus. The company's cancer program comprises IMO-2055, which has completed Phase Ib clinical trials for treatment of non-small cell lung cancer; and has completed Phase II clinical trials for the treatment of squamous cell, head and neck, and colorectal cancer. It is also developing IMO-2134 that has completed Phase I clinical trials to treat asthma and allergy. In addition, the company's research candidates include IMO-4200 for hematologic malignancies; and TLR3 Agonists for infectious diseases and other applications, as well as gene silencing oligonucleotides for inhibition of gene expression by targeting RNA. The company has license agreement with Merck KGaA to research, develop, and commercialize products containing its TLR9 agonists for the treatment of cancer; and license and research collaboration agreement with Merck Sharp & Dohme Corp. to research, develop, and commercialize vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer's disease. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.
Health Biotechnology Cancer Biology Infectious Diseases Treatment Of Cancer Clinical Trial Non Small Cell Lung Cancer Alzheimer's Disease Genetics Psoriasis Asthma Gene Expression Allergy Colorectal Cancer Hematologic Malignancies Autoimmune And Inflammatory Diseases RNA Treatment Of Non Small Cell Lung Cancer Treatment Of Autoimmune And Inflammatory Diseases Treatment Of Psoriasis United Nations Tlr7 Tlr9 Vaccine Products
Is IDRA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 17.12
52 Week Low 2.25
Average Volume 359,320
200-Day Moving Average 6.7418
50-Day Moving Average 2.7874
20-Day Moving Average 2.8685
10-Day Moving Average 2.915
Average True Range 0.259
ADX 16.09
+DI 19.1893
-DI 20.1351
Chandelier Exit (Long, 3 ATRs ) 2.553
Chandelier Exit (Short, 3 ATRs ) 3.227
Upper Bollinger Band 3.148
Lower Bollinger Band 2.589
Percent B (%b) 0.23
BandWidth 19.487537
MACD Line 0.0248
MACD Signal Line 0.005
MACD Histogram 0.0198
Fundamentals Value
Market Cap 406.99 Million
Num Shares 150 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -8.00
Price-to-Sales 13.60
Price-to-Book 2.94
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.20
Resistance 3 (R3) 3.23 3.11 3.12
Resistance 2 (R2) 3.11 2.98 3.09 3.09
Resistance 1 (R1) 2.91 2.91 2.85 2.88 3.07
Pivot Point 2.79 2.79 2.76 2.77 2.79
Support 1 (S1) 2.59 2.66 2.53 2.56 2.37
Support 2 (S2) 2.47 2.59 2.45 2.35
Support 3 (S3) 2.27 2.47 2.32
Support 4 (S4) 2.24